ampicillin "mylan" 250 mg pulver til injektions-/infusionsvæske, opløsning
mylan pharmaceuticals limited - ampicillinnatrium - pulver til injektions-/infusionsvæske, opløsning - 250 mg
clopidogrel "splendris" 75 mg filmovertrukne tabletter
splendris pharmaceuticals gmbh - clopidogrelhydrogensulfat - filmovertrukne tabletter - 75 mg
ladoxyn 500 mg/g granulat til oral opløsning
lavet pharmaceuticals ltd. - doxycyclinhyclat - granulat til oral opløsning - 500 mg/g - fjerkræ, svin
oxcarbazepin "jubilant" 150 mg filmovertrukne tabletter
jubilant pharmaceuticals nv - oxcarbazepin - filmovertrukne tabletter - 150 mg
noromylin vet. 100 mg/ml injektionsvæske, opløsning
scanvet animal health a/s - lincomycinhydrochlorid - injektionsvæske, opløsning - 100 mg/ml - hund, kat, svin
lincocin vet. 100 mg/ml injektionsvæske, opløsning
zoetis finland oy - lincomycinhydrochlorid - injektionsvæske, opløsning - 100 mg/ml - hund, kat, svin
rosuvastatin "glenmark" 5 mg filmovertrukne tabletter
glenmark arzneimittel gmbh - rosuvastatin calcium - filmovertrukne tabletter - 5 mg
jalra
novartis europharm limited - vildagliptin - diabetes mellitus, type 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).
ezetimibe "orion" 10 mg tabletter
orion corporation - ezetimib - tabletter - 10 mg
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - carcinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.